Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-n... Author: imedex Added: 10/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts